Tudor Investment Corp ET AL Sells 23,502 Shares of Retrophin, Inc. (RTRX)

Tudor Investment Corp ET AL lowered its stake in shares of Retrophin, Inc. (NASDAQ:RTRX) by 38.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,231 shares of the biopharmaceutical company’s stock after selling 23,502 shares during the quarter. Tudor Investment Corp ET AL owned about 0.10% of Retrophin worth $741,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently modified their holdings of the company. SG Americas Securities LLC raised its stake in Retrophin by 1.8% in the second quarter. SG Americas Securities LLC now owns 8,167 shares of the biopharmaceutical company’s stock valued at $158,000 after buying an additional 146 shares during the last quarter. Ameriprise Financial Inc. raised its stake in Retrophin by 1.0% in the second quarter. Ameriprise Financial Inc. now owns 30,520 shares of the biopharmaceutical company’s stock valued at $592,000 after buying an additional 290 shares during the last quarter. Legal & General Group Plc raised its stake in Retrophin by 4.3% in the second quarter. Legal & General Group Plc now owns 8,664 shares of the biopharmaceutical company’s stock valued at $168,000 after buying an additional 355 shares during the last quarter. AJO LP raised its stake in Retrophin by 1.9% in the second quarter. AJO LP now owns 59,681 shares of the biopharmaceutical company’s stock valued at $1,157,000 after buying an additional 1,094 shares during the last quarter. Finally, Parametric Portfolio Associates LLC raised its stake in Retrophin by 3.7% in the second quarter. Parametric Portfolio Associates LLC now owns 33,471 shares of the biopharmaceutical company’s stock valued at $649,000 after buying an additional 1,200 shares during the last quarter.

Shares of Retrophin, Inc. (RTRX) opened at 24.72 on Friday. The firm has a 50-day moving average price of $23.99 and a 200-day moving average price of $20.09. Retrophin, Inc. has a 1-year low of $15.55 and a 1-year high of $25.44. The stock’s market capitalization is $948.88 million.

Retrophin (NASDAQ:RTRX) last released its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.10). The business had revenue of $38.80 million for the quarter, compared to analyst estimates of $37.36 million. Retrophin had a negative return on equity of 7.31% and a negative net margin of 48.74%. The company’s revenue was up 16.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.07 earnings per share. On average, equities research analysts forecast that Retrophin, Inc. will post ($1.13) earnings per share for the current year.

In related news, COO Neil F. Mcfarlane sold 1,378 shares of the company’s stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $22.50, for a total value of $31,005.00. Following the completion of the sale, the chief operating officer now directly owns 13,622 shares of the company’s stock, valued at approximately $306,495. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 2.41% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: “Tudor Investment Corp ET AL Sells 23,502 Shares of Retrophin, Inc. (RTRX)” was published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://transcriptdaily.com/2017/10/08/tudor-investment-corp-et-al-sells-23502-shares-of-retrophin-inc-rtrx.html.

RTRX has been the subject of a number of research analyst reports. ValuEngine upgraded Retrophin from a “sell” rating to a “hold” rating in a research note on Friday, August 4th. BidaskClub upgraded Retrophin from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 24th. Finally, BMO Capital Markets reiterated a “buy” rating and issued a $44.00 price target on shares of Retrophin in a research note on Friday. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $36.00.

About Retrophin

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

Institutional Ownership by Quarter for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply